TheStreet downgrades Boston Scientific — 3 insights

TheStreet downgraded Boston Scientific from a "B" to a "C" rating in a recent research report.

Here's what you should know.

1. TheStreet joins several other analysts in downgrading the industry giant.

2. Yet, despite the recent downgrades, Boston Scientific still has 13 "buy" ratings, six "hold" ratings and a single "sell" rating.

3. Analysts attached an average price target of $31.06 per share to the stock.

More articles on supply chain: 
Riverside Regional Surgery Center owner, 3 others charged in $8M healthcare fraud scheme: 5 things to know
ASC physician and equity ownership preferences — 14 statistics
What ASCs can do to reduce SSI

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months